Trials / Not Yet Recruiting
Not Yet RecruitingNCT07141810
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
Early Antifibrotic Therapy for f-ILD
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Early antifibrotic therapy for f-ILD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antifibrotic drugs (nidanib or pirfenidone) | One group received primary therapy, and another group received an antifibrotic drug (nidanib or pirfenidone) in addition to primary therapy. |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2028-04-30
- Completion
- 2028-05-30
- First posted
- 2025-08-26
- Last updated
- 2025-08-26
Source: ClinicalTrials.gov record NCT07141810. Inclusion in this directory is not an endorsement.